VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL12 2022 | The value of CAR-T cell therapy in R/R DLBCL

Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, briefly comments on the value of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), highlighting the results of the TRANSFORM (NCT03575351) and ZUMA-7 (NCT03391466) trials. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter